ABSTRACT
Somatostatin receptors are members of G-protein coupled receptor superfamily. Receptors can be classified into five subtypes, SSTR1 to 5. The highly potent and orally active SSTR2 agonist 7, which had been identified by our group, was found out to have toxicological liabilities such as hERG inhibition and phospholipidosis (PLD). We investigated the relationship between in silico physicochemical properties and hERG and PLD, and explored well-balanced agonists to identify amide 19 and benzimidazole 30. As a result of this exploration, we found out that the value of (cLogP) [2] + (pKa) [2] needs to be less than 110 to mitigate the liabilities.
Subject(s)
Amides/pharmacology , Benzimidazoles/pharmacology , Drug Design , Ether-A-Go-Go Potassium Channels/antagonists & inhibitors , Phospholipids/antagonists & inhibitors , Receptors, Somatostatin/agonists , Amides/chemical synthesis , Amides/chemistry , Benzimidazoles/chemical synthesis , Benzimidazoles/chemistry , Dose-Response Relationship, Drug , Ether-A-Go-Go Potassium Channels/metabolism , Humans , Molecular Structure , Phospholipids/metabolism , Structure-Activity RelationshipABSTRACT
Acromegaly is a disease caused by the oversecretion of growth hormone. It is currently treated by intravenous injection with cyclic peptide drugs that activate somatostatin receptor subtype 2 (SSTR2). Here, novel nonpeptidic, small-molecule, and orally active SSTR2 agonists were identified from a hit compound (13). Pharmacophore studies enabled scaffold hopping to obtain a unique 3,4,5-trisubstituted pyridine motif. Further optimization conferred potent SSTR2 agonistic activity and metabolic stability. Several compounds were evaluated and these showed good oral pharmacokinetic profiles in rats, and one representative compound (25) showed highly potent inhibition of growth hormone secretion induced by growth hormone-releasing hormone in rats. Based on these results, 25 was identified as a promising lead for further optimization. A structure-activity relationship (SAR) study and the metabolic stability data for this compound are also described.
Subject(s)
Acromegaly , Acromegaly/drug therapy , Animals , Growth Hormone , Rats , Receptors, Somatostatin/agonists , Somatostatin , Structure-Activity RelationshipABSTRACT
The structure of the S1P2 antagonist 1 has been modified with the aim of improving its oral bioavailability. The chemical modification of the alkyl chain and carboxylic acid moieties of 1 led to significant improvements in the oral exposure of compounds belonging to this series. The optimization of the ring size of the urea portion of these molecules also led to remarkable improvements in the oral exposure. Based on these changes, the pyrrolidine derivative 16 was identified as a suitable candidate compound and showed excellent pharmacokinetic profiles in rat and dog, while maintaining high levels of potency and selective antagonistic activity toward S1P2.
Subject(s)
Benzene Derivatives/chemistry , Receptors, Lysosphingolipid/antagonists & inhibitors , Administration, Oral , Animals , Benzene Derivatives/chemical synthesis , Benzene Derivatives/pharmacokinetics , Biological Availability , Dogs , Drug Evaluation, Preclinical , Half-Life , Haplorhini , Pyrrolidines/chemical synthesis , Pyrrolidines/chemistry , Pyrrolidines/pharmacokinetics , Rats , Receptors, Lysosphingolipid/metabolism , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
Our initial lead compound 2 was modified to improve its metabolic stability. The resulting compound 5 showed excellent metabolic stability in rat and human liver microsomes. We subsequently designed and synthesized a hybrid compound of 5 and the 1,3-bis(aryloxy) benzene derivative 1, which was previously reported by our group to be an S1P2 antagonist. This hybridization reaction gave compound 9, which showed improved S1P2 antagonist activity and good metabolic stability. The subsequent introduction of a carboxylic acid moiety into 9 resulted in 14, which showed potent antagonist activity towards S1P2 with a much smaller species difference between human S1P2 and rat S1P2. Compound 14 also showed good metabolic stability and an improved safety profile compared with compound 9.
Subject(s)
Benzene Derivatives/pharmacology , Drug Discovery , Receptors, Lysosphingolipid/antagonists & inhibitors , Animals , Benzene Derivatives/chemistry , Benzene Derivatives/metabolism , Dose-Response Relationship, Drug , Humans , Molecular Structure , Rats , Receptors, Lysosphingolipid/metabolism , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.
Subject(s)
Asthma/drug therapy , Butyrates/pharmacology , Butyrates/therapeutic use , Indoles/pharmacology , Indoles/therapeutic use , Leukotriene Antagonists/pharmacology , Leukotriene Antagonists/therapeutic use , Receptors, Leukotriene/drug effects , Animals , Biological Availability , Dogs , Guinea Pigs , Humans , Leukotriene Antagonists/pharmacokinetics , RatsABSTRACT
The structure-activity relationships of a novel series of sphingosine-1-phosphate receptor antagonists have been examined in detail. The initial hit compound 1 was modified through synthesis to improve its S1P2 activity. The synthesis of a series of analogs revealed that 1,3-bis(aryloxy)benzene derivatives, as represented by 22, are potent and selective S1P2 antagonists.
Subject(s)
Benzene Derivatives/pharmacology , Drug Discovery , Receptors, Lysosphingolipid/antagonists & inhibitors , Benzene Derivatives/chemical synthesis , Benzene Derivatives/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Sphingosine-1-Phosphate Receptors , Structure-Activity RelationshipABSTRACT
A potent, orally available dual CysLT1 and CysLT2 receptor antagonist with a dicarboxylic acid is described. 4-(3-(Carboxymethyl)-4-{(E)-2-[4-(4-phenoxybutoxy)phenyl]vinyl}-1H-indol-1-yl)butanoic acid (15: ONO-4310321, IC50: CysLT1=13nM, CysLT2=25 nM) showed excellent pharmacokinetic profiles (%Frat=100) compared with our previously reported compound 1 (%Frat=1.5). In addition, we describe a new rule for dicarboxylic acid derivatives to show good oral bioavailability (%Frat⩾40) in rats (HBDs: ⩽2, ClogP: >6.5 and TPSA: <100). Especially, reduction of only one hydrogen-bond donor (HBDs) showed dramatically improved oral bioavailability. This small change of HBDs in dicarboxylic acid derivatives is generally a very effective modification.
Subject(s)
Dicarboxylic Acids/administration & dosage , Dicarboxylic Acids/pharmacology , Drug Discovery , Leukotriene Antagonists/administration & dosage , Leukotriene Antagonists/pharmacology , Receptors, Leukotriene/metabolism , Administration, Oral , Animals , Biological Availability , CHO Cells , Caco-2 Cells , Cricetulus , Dicarboxylic Acids/chemistry , Dose-Response Relationship, Drug , HEK293 Cells , Humans , Leukotriene Antagonists/chemistry , Molecular Structure , Structure-Activity RelationshipABSTRACT
The benzoxazine derivative, (2S)-4-(3-carboxypropyl)-8-{[4-(4-phenylbutoxy)benzoyl]amino}-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid (19, ONO-2050297), was identified as the first potent dual CysLT1 and CysLT2 antagonist with IC50 values of 0.017 µM (CysLT1) and 0.00087 µM (CysLT2), respectively.